The Washington Sun

Main Navigation

Subscribe Log in
  • Newsletters
    • Sign up for our newsletters
    • The Washington Sun newsletter
    • Afternoon Sun
    • Metro
    • Sign up for Dana Milbank’s newsletter
    • Sign up for Matt K. Lewis’ newsletter
  • Weather
  • Campaigns
    • 2026 Election
    • 2028 Election
    • Democrats
    • Republicans
    • Influence
  • Congress
    • House
    • Senate
  • Metro
    • Latest in Metro
    • Tom Sietsema
  • Sports
    • Latest in Sports
    • All-DMV High School
  • Policy
    • Administration
    • Defense
    • Energy & Environment
    • Immigration
    • Economy
    • Health
    • Foreign Policy
    • Housing
    • Technology
  • National
    • Legal
    • U.S. News
  • Perspectives
    • Latest Perspectives
    • Dana Milbank
    • Matt K. Lewis
    • Features
    • Forums
  • Podcast
    • Washington Sun Cast • Episode List
    • Milbank & Lewis • Episode List
  • Who Are We?
    • About The Washington Sun
    • Events
    • Work for us
    • Press Releases
    • Support FAQ
  • Follow Us
    • X (Twitter)
    • Bluesky
    • LinkedIn
    • Instagram
    • TikTok
    • YouTube
Subscribe
Log in

Support independent journalism. Subscribe for $50 for your first year. Limited time.

Health Care

FDA Says Its Safety Review of Abortion Pill Will Continue Into Next Year

In addition to the safety study, the agency said it is considering a number of petitions proposing changes to how mifepristone is prescribed and distributed.

Mifepristone

Charlie Neibergall/AP

By The Associated Press

October 8, 2026 08:59 a.m.

  • Email
  • LinkedIn
  • Twitter
  • Copy
    Link copied

By Matthew Perrone

WASHINGTON (AP) — The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents hoping to see the drug’s use curtailed.

The FDA gave a court-ordered update on its progress in a legal filing late Wednesday, providing the first substantive information about the controversial reevaluation ordered by Health Secretary Robert F. Kennedy Jr.

Mifepristone was first approved by the FDA in 2000. The agency has repeatedly reaffirmed the pill’s safety and effectiveness over the years, in addition to easing a number of restrictions on the drug, including dropping a requirement that it be dispensed in person.

Trending

  • KirstenDavies

    Top Defense Official Purchased Stock in Defense Companies

  • AP060612032023.jpg

    Trump Administration Says It Can Detonate Iowa Lead Despite Court Order

  • Trump paper AP - 26155707137628

    Whistleblowers Tell Democrats the Trump Administration is Destroying Documents

  • DonaldTrumpAI

    White House Limits Federal Contractors’ Ability to Respond to Democratic-Led Investigations

But since President Donald Trump returned to the White House, anti-abortion groups and their allies in Congress have pushed the administration to revisit the pill, in the hopes of restricting its use.

The FDA said in its filing that it expects to complete a safety study of the pill by mid-December this year. A report on the findings is expected “no later than March 2027,” after which the agency will decide whether to impose new restrictions or other changes on the drug’s use.

Gavin Oxley of Americans United for Life, an anti-abortion group, criticized the move as a lack of “true leadership” by Trump administration officials.

“The administration continues to find itself on the wrong side of women’s health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill,” Oxley said.

The two-drug regimen of mifepristone, combined with a second drug misoprostol, is the most common form of abortion in the U.S.

The FDA was directed to provide the latest update by a federal judge in a case brought by the state of Louisiana alleging that mail-delivery of mifepristone undermines the state’s abortion ban. It’s one of several state lawsuits related to mifepristone winding their way through the courts.

Last month a three-judge panel for the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana’s case, including whether the state had the legal standing to challenge FDA’s oversight of mifepristone.

Any ruling from the 5th Circuit on the Louisiana case would not immediately change the landscape because the Supreme Court has blocked changes to the drug until it sees the case again.

The FDA said Wednesday it is using a “statistical data mining method” to discover “unknown safety concerns,” that may exist with the drug. The data comes from an electronic database that collects reports of medical injuries and drug side effects from major health networks and insurers.

In addition to the safety study, the agency said it is considering a number of petitions proposing changes to how mifepristone is prescribed and distributed.

Abortion opponents have focused most of their efforts on a 2021 decision allowing doctors to prescribe the drug online and send it through the mail during COVID-19. That decision, made permanent under President Joe Biden in 2023, had the effect of undermining a number of state abortion bans, since women can receive the drug through the mail.

Author

Associated-Press_author_IMG-360px.png The Associated Press

The Latest

  • Trinity Rodman AP - 26326083667852

    The Spirit Is Denied Its Championship Moment in a 2-1 Loss to the Current

  • Trump

    Trump Signals Further Interest in Working With Democrats on ‘TrumpCare’

  • Light shines on the U.S. Capitol dome on Capitol Hill in Washington.

    Fifth Circuit Upholds Texas’ Block on Enforcing a Federal Pregnant Workers Law

  • Elizabeth Warren

    Trump Says He’ll Work With Democrats to Cap Credit Card Interest Rates

  • DonaldTrumpAI

    White House Limits Federal Contractors’ Ability to Respond to Democratic-Led Investigations

Welcome back to The Washington Sun!

You can always update your profile and newsletters preferences on the My Account page.

Manage account settings

Welcome to
The Washington Sun

Subscribe to maintain unlimited access to independent journalism covering Washington's people, politics and power.

Continue to checkout ↗
  • About The Washington Sun
  • Work for us
  • Terms of Use
  • Subscription Agreement Terms and Conditions
  • Privacy Policy
  • Your CA Privacy Rights
  • Support FAQ
  • Contact us

© 2026.0 NOTUS MEDIA, LLC